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ABSTRACT 1 
Background: Dysfunction of the gut microbiota is frequently reported as a manifestation of 2 
chronic disease, and therefore presents as a modifiable risk factor in their development. Diet is 3 
a major regulator of the gut microbiota and certain types of dietary fiber may modify bacterial 4 
numbers and metabolism, including short-chain fatty acid (SCFA) generation. 5 
Objective: A systematic review and meta-analysis were undertaken to assess the effect of 6 
dietary fiber interventions on gut microbiota composition in healthy adults. 7 
Design: A systematic search was conducted across MEDLINE, EMBASE, CENTRAL and 8 
CINAHL for randomized controlled trials using culture and/or molecular microbiological 9 
techniques evaluating the effect of fiber intervention on gut microbiota composition in healthy 10 
adults. Meta-analyses using random-effects model were performed on alpha diversity, pre-11 
specified bacterial abundances including Bifidobacterium and Lactobacillus spp., and fecal 12 
SCFA concentrations comparing dietary fiber intervention with placebo/low fiber 13 
comparators. 14 
Results: A total of 64 studies involving 2099 participants were included. Dietary fiber 15 
intervention resulted in higher abundance of Bifidobacterium spp. [Standardized Mean 16 
Difference (SMD) 0.64 (95% Confidence Interval: 0.42, 0.86]; P < 0.00001] and Lactobacillus 17 
spp. [SMD: 0.22 (0.03, 0.41), P = 0.02] as well as fecal butyrate concentration [SMD: 0.24 18 
(0.00, 0.47), P = 0.05] compared with placebo/low fiber comparators. Subgroup analysis 19 
revealed fructans and galacto-oligosaccharides led to significantly greater abundance of both 20 
Bifidobacterium spp. and Lactobacillus spp. compared with comparators (P < 0.00001 and P = 21 
0.002 respectively). No differences in effect were found between fiber intervention and 22 
comparators for α-diversity, abundances of other pre-specified bacteria, or other SCFA 23 
concentrations. 24 
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Conclusion: Dietary fiber intervention, particularly involving prebiotic fibers, leads to higher 25 
fecal abundance of Bifidobacterium and Lactobacillus spp. but does not impact α-diversity. 26 
Further research is required to better understand the role of individual fiber types on the 27 
growth of microbes and the overall gut microbial community. 28 
KEYWORDS 29 
Diet, dietary fiber, gastrointestinal microbiome, gastrointestinal microbiota, gut microbiota, 30 
prebiotic  31 
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BACKGROUND 32 
The gut microbiota is a highly diverse and metabolically active community, consisting of 33 
approximately 3.9 x 1013 microbial cells (1). These microbes participate in several functions 34 
beneficial to the host, including the fermentation of undigested nutrients (2, 3), synthesis of 35 
vitamins (4) and interaction with the immune system (5, 6). A number of disorders, including 36 
irritable bowel syndrome and type 2 diabetes mellitus, have been linked with disturbances in 37 
gut microbiota composition (2, 7-9). Such an association presents the gut microbiota as a 38 
potentially modifiable risk factor in the etiology of these conditions. 39 
The gut microbiota can be detected and enumerated using different methods ranging from 40 
culture to next-generation sequencing (6, 10, 11), and can be characterized by measures of 41 
diversity and bacterial abundances (12, 13). Alpha diversity of the gut microbiota describes the 42 
richness (number of taxonomically distinct organisms present) and evenness (relative 43 
abundances of organisms) of its composition (12, 13), with cross-sectional studies 44 
demonstrating inverse associations between α-diversity and disease states (7-9). Specific 45 
bacteria shown to be more abundant in health compared with disease states include 46 
Bifidobacterium and Lactobacillus spp. (2, 7, 14), whose functions include carbohydrate 47 
fermentation and vitamin synthesis (15-18). Furthermore, increasing evidence supports the 48 
importance of ‘keystone’ bacterial species, whose absence may have profound consequences 49 
for the host, as well as other members of the microbial community and their metabolic outputs, 50 
including the short-chain fatty acid (SCFA) butyrate (19-23). Butyrate is of particular interest 51 
to health due to its beneficial properties such as its immunomodulatory effects (24, 25). 52 
Dietary fiber is defined as non-digestible carbohydrates of ≥ 3 monomeric units found 53 
inherently in foods, and also includes isolated or synthetic fibers with demonstrated 54 
physiological benefits (26-28). It is a key candidate in facilitating changes in the gut 55 
microbiota, as it escapes digestion by the host in the small intestine to pass into the colon 56 
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where it is available to the microbial community. Dietary fiber encompasses an array of 57 
heterogeneous compounds whose physicochemical properties vary based on their particle size, 58 
chemical structure, solubility, viscosity and fermentability (29, 30). Fiber with fermentable 59 
characteristics are substrates for the microbial population in the colon, stimulating growth of 60 
specific organisms and leading to production of various metabolites including SCFA (19, 29, 61 
31). Indeed, some fibers can be further classified as ‘prebiotic’ (e.g. fructans) if they have been 62 
shown to be selectively utilized by host microorganisms conferring a health benefit (32). 63 
The current body of evidence regarding the effect of dietary fiber on the gut microbiota is 64 
informed via specific prebiotic fiber interventions (33, 34), whole-diet interventions (35-37) 65 
and cross-sectional associations (38, 39). However, these investigations are limited in that 66 
prebiotic fibers represent only a subset of total dietary fiber, and confounding factors such as 67 
disease states and intake of other fermentable substrates, are unaccounted for in whole diet 68 
studies and cross-sectional studies (40). Therefore, there is a gap in knowledge regarding the 69 
precise impact of dietary fiber intervention on the gut microbiota in healthy subjects, and this 70 
is the focus on the systematic review.  71 
METHODS 72 
This systematic review was conducted in line with the guidelines of the Preferred Reporting 73 
Items for Systematic Reviews and Meta-Analysis: The PRISMA statement (41), and the 74 
guidelines of the Cochrane Handbook for Systematic Reviews and Interventions (42). The 75 
methods including the eligibility criteria, search strategy, extraction process and analysis were 76 
pre-specified and documented in a protocol that was published in the International Prospective 77 
Register of Systematic Reviews (CRD42016053101). 78 
Literature search 79 
A literature search was performed in the electronic databases MEDLINE, EMBASE, 80 
CENTRAL and CINAHL (from inception to October 4, 2017), using a combination of subject 81 
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headings, free text terms and synonyms relevant to this review, in consultation with an 82 
experienced systematic review search librarian (Supplemental Tables 1-4). There was no date 83 
or language restriction in the search strategy. A multi-step search approach was taken to 84 
retrieve relevant studies through additional hand-searching; contacting field experts; searching 85 
conference abstracts; theses and dissertations (ProQuest); and the International Clinical Trials 86 
Register (ICTRP) Search Portal and ClinicalTrials.gov to identify ongoing trials. Two review 87 
authors (DS and HS) screened articles in a blinded, standardized manner, with disagreements 88 
in judgement resolved by consensus or a third reviewer (KC). 89 
Study selection 90 
Search results were merged into reference management software Endnote (X7; Thomson 91 
Reuters) and de-duplicated prior to screening using Rayyan (Qatar Computing Research 92 
Institute) (43). Full text articles of potentially relevant studies were sought and reviewed. 93 
Attempts were made to contact the corresponding author where the full text article provided 94 
inadequate information to assess eligibility or extract relevant data. Studies were included if 95 
they met all of the following criteria: 1) randomized controlled trial (RCT), cluster RCT, or 96 
quasi-RCT; 2) inclusion of healthy adult participants (≥18 years of age); 3) intervention aimed 97 
at increasing fiber intake; 4) inclusion of a placebo for supplement interventions (e.g. 98 
maltodextrin), and either low fiber control (e.g. white bread) or habitual diet group for food 99 
interventions as comparators; 5) measured fecal microbiota related outcomes at the end of 100 
intervention. 101 
Studies that were solely investigating enteral nutrition and those that included participants with 102 
an acute or chronic disease, including gastrointestinal (GI) conditions such as coeliac disease, 103 
inflammatory bowel disease, irritable bowel syndrome and other functional gastrointestinal 104 
disorders were excluded. Studies including mixed population groups where the healthy sub-105 
group was not reported separately were also excluded. Studies that included overweight and 106 
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obese participants who were otherwise healthy and without any abnormal clinical parameters 107 
(e.g. elevated blood pressure) were included. Interventions eligible for inclusion provided an 108 
increase in fiber intake achieved through 1) dietary counselling to increase dietary fiber intake 109 
from food 2) food intervention (e.g. added cereals); or 3) fiber supplementation. Dietary 110 
counselling studies or food interventions were only included if fiber modification was the 111 
primary aim of the intervention. 112 
The primary outcome was between-group differences in α-diversity of fecal microbiota at the 113 
end of the intervention. Measures of α-diversity included the total number of observed 114 
operational taxonomic units (OTUs) (the number of taxonomically-related groups of bacteria, 115 
evaluating richness); Chao1 Index (a non-parametric richness estimator); Shannon diversity 116 
index (a metric combining richness and evenness, with equal weighting to abundant and rare 117 
species); and Simpson diversity index (metric of richness and evenness, where more weighting 118 
is given to abundant species). Secondary outcomes were between-group differences in 119 
abundances of the following commonly measured bacterial groups: Bifidobacterium spp.; 120 
Lactobacillus spp.; Roseburia spp.; Akkermansia muciniphila; Eubacterium hallii; 121 
Eubacterium rectale; Faecalibacterium prausnitzii; and Ruminococcus bromii. Studies were 122 
included if they reported on either primary or secondary outcomes. Between-group differences 123 
in fecal SCFAs (total SCFAs and butyrate) were included as an exploratory outcome. 124 
Data extraction and management 125 
Two reviewers (DS and HS) independently extracted the data from eligible studies. Data 126 
extracted included: study design (duration, location, details of ‘run-in’ and ‘wash-out’ 127 
periods); participant characteristics, intervention details (fiber type, fiber dose, intervention 128 
delivery, compliance, assessment and control of dietary intake); and other information 129 
including antibiotic or probiotic use. 130 
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For all pre-specified primary, secondary and exploratory outcome data, the mean, standard 131 
deviation (SD), standard error (SE) or 95% confidence intervals (CI) that were reported at end 132 
of intervention were extracted for analysis. Where studies used multiple intervention groups of 133 
different fiber doses, data for the highest intervention dose was extracted. Where studies used 134 
multiple intervention groups of different fibers at the same dose compared with a single 135 
control group, data was extracted from each intervention group and pooled together. A 136 
weighted average of the intervention groups and the study variance was then calculated (44). 137 
Risk of bias was independently assessed by two reviewers (DS and HS) using Cochrane 138 
methodology (45). The review assessed “other bias” regarding the control of dietary intake 139 
during the study. This included examining whether dietary advice (e.g. to maintain dietary 140 
intake or avoid probiotic food sources) was provided, whether dietary compliance and/or 141 
intake were measured and reported, and if adjustments in statistical analysis were made if 142 
differences in dietary intake were found. 143 
Statistical analysis 144 
The overall treatment effect of fiber on primary and secondary outcomes was calculated using 145 
the difference between the end of intervention values for the intervention and comparator 146 
groups.  Data reported as median and interquartile range were converted to mean and SD as 147 
previously described (46). Variance was calculated from the SD and SE of end of intervention 148 
values, or from the confidence intervals (CI) where these values were not available (46). In 149 
crossover studies, the mean and SD, SE or CI of intervention and control periods were 150 
extracted and analyzed separately (47). Where end of intervention endpoint data was unable to 151 
be obtained, the results were described in text only. 152 
Meta-analysis was performed where outcomes were reported in at least two studies using 153 
Revman (Version 5.3; Cochrane Collaboration). The mean difference (MD) was used to 154 
calculate effect sizes where outcome data were presented in the same units (Shannon diversity 155 
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index, total number of observed OTUs). Where outcome data were reported using different 156 
units, effect sizes were calculated using the standardized mean difference (SMD) (bacterial 157 
abundances, fecal SCFA concentration).  158 
A random-effects model was used to produce a pooled estimate of the MD or SMD, and the 159 
fixed-effects model was used to check for robustness and potential outliers. Inconsistencies 160 
between studies were assessed using the I2 statistic, where significant heterogeneity was 161 
defined as I2 ≥ 50%. 162 
Pre-defined subgroup analyses were undertaken for primary and secondary outcomes that were 163 
reported in at least two studies in each subgroup. Pre-defined subgroup analyses included 164 
intervention types (supplements and dietary interventions), fiber types (accepted and candidate 165 
prebiotic fibers defined by Roberfroid et al., and general fibers defined by the review) (34), 166 
dose-response (comparing difference in fiber intake between intervention and control group of 167 
≤5g/d, 5-10g/d, and >10g/d), trial design (parallel and crossover), and microbial analysis 168 
method (e.g. culture, sequencing). Post hoc subgroup analyses were undertaken for exploratory 169 
outcomes based on reporting method of fecal SCFA concentrations (dry weight of feces and 170 
wet weight of feces). Fructans and galacto-oligosaccharides were classified as ‘accepted 171 
prebiotic’ fibers, while ‘candidate prebiotic’ fibers included a broader range of fibers including 172 
polydextrose and resistant starch (34). The term ‘general fiber’ was used by the review to 173 
describe fibers not classified as either accepted or candidate prebiotics, and is not a formal 174 
term used to describe fibers in the literature. 175 
For the fiber type subgroup analysis only, the fiber arm with the highest prebiotic classification 176 
(e.g. accepted prebiotic as opposed to a general fiber) was selected if multiple intervention 177 
groups were reported. Where multiple arms of the same prebiotic classification were 178 
presented, the interventions were pooled together and a weighted average of the intervention 179 
arms and study variance were calculated (44). Significant outliers were determined by visual 180 
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inspection as well as through a study-by-study sensitivity analysis, where each study was 181 
sequentially omitted and the remaining data re-assessed. If a study contributed to over 30% 182 
heterogeneity (based on changes to the I2 statistic) then it was removed from the analysis in the 183 
sensitivity analysis. Funnel plots were generated for outcomes where at least 10 studies were 184 
included in meta-analysis (48) and reporting bias detected by assessment of funnel plot 185 
asymmetry by visual inspection. 186 
RESULTS 187 
Study characteristics 188 
Study identification and selection are detailed in the PRISMA flow chart (Figure 1). The 189 
initial electronic and manual search generated 3829 records. After review of full texts 190 
(Supplemental Table 5), 64 publications, along with three secondary studies (49-51) 191 
reporting additional outcomes from the primary publications, fulfilled the inclusion criteria 192 
and were included in the review. 193 
The 64 included primary studies that analyzed a total of 2099 participants. Of these 64 studies, 194 
29 were parallel RCTs (52-80) and 35 were crossover RCTs (81-115). Five crossover trials did 195 
not include a wash out period (84, 93, 95, 105, 108). The majority of studies (52 studies) used 196 
fiber supplementation, including: accepted prebiotic fiber (26 studies) (52, 54-58, 61, 62, 65, 197 
67, 70, 74, 86, 90, 92, 95, 97, 100, 102, 103, 105, 107, 109-111, 115); candidate prebiotic fiber 198 
(18 studies) (53, 63, 64, 66, 68, 69, 73, 77, 81, 83, 84, 87, 88, 91, 99, 101, 112, 113); general 199 
fiber (seven studies) (59, 60, 72, 76, 80, 93, 94); and a fiber mix (108). The remaining 12 200 
studies used food intervention by providing key food items (e.g. wholegrain cereal) to 201 
supplement the diet (71, 78, 82, 85, 89, 96, 98) or provided all food and fluid to participants 202 
(75, 79, 104, 106, 114). Intervention doses ranged from 1.2 g/d to 50 g/d, while treatment 203 
periods ranged from five days to three months, with a median length of three weeks. 204 
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Analysis techniques used to characterize fecal microbiota included: culture (15 studies) (52, 205 
54-58, 65, 66, 69, 71, 73, 96, 98, 105, 114); fluorescence in situ hybridization (FISH) (20 206 
studies) (53, 70, 74, 76, 82, 85, 89-92, 94, 99, 100, 103, 106, 108-110, 112, 113); quantitative 207 
polymerase chain reaction (qPCR) (11 studies) (60, 63, 68, 81, 86, 87, 95, 102, 104, 107, 111); 208 
and next-generation sequencing (including 454 pyrosequencing and Illumina sequencing) (12 209 
studies) (59, 62, 64, 72, 75, 77-80, 97, 101, 115). A combination of techniques were used in 210 
six studies (49, 61, 67, 83, 84, 88, 93). 211 
The outcomes of each meta-analysis are reported in Table 1. Results from subgroup analyses 212 
performed are included in Supplemental Table 6. Overall, outcome data from 56 studies were 213 
suitable for meta-analysis; results from the following studies were unable to be statistically 214 
pooled and are presented narratively under their respective sub-headings (59, 62, 69, 77-79, 215 
83, 93, 95, 97, 101, 113, 115). The characteristics of included studies are presented in Tables 216 
2-3. 217 
Dietary fiber and gut microbiota diversity (α-diversity) 218 
Alpha-diversity was measured in 13 studies involving 393 participants (49, 59, 64, 72, 75, 77, 219 
79, 80, 83, 88, 93, 97, 101). 220 
Ten studies reported α-diversity using Shannon diversity index. Of these, six reported the 221 
metric in a form suitable for inclusion in the meta-analysis (49, 64, 72, 75, 80, 88). Dietary 222 
fiber intervention had no effect on α-diversity compared with placebo/low fiber comparators 223 
[MD: -0.06 Shannon diversity index (95% CI: -0.25, 0.12), P = 0.48], albeit with substantial 224 
heterogeneity (I2 = 53%). In two of the studies not included in the meta-analysis, raffinose and 225 
resistant starch interventions did not lead to significant difference in α-diversity compared with 226 
placebo (93, 101). A significant reduction in the α-diversity of fecal microbiota from baseline 227 
was detected in a trial involving flaxseed mucilage, measured by both the exponential of 228 
Shannon diversity index [-38010 (95% CI: -64473, -11546, P = 0.007)] as well as through 229 
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Simpson’s inverse index [-17515 (95% CI: -30992, -4038, P = 0.014)], although a between-230 
group comparison was not reported (59). Conversely, significant end of intervention 231 
differences in α-diversity measured by Shannon diversity index (P = 0.013) and inverse 232 
Simpson index (P =0.004) were detected between intervention and comparator groups in a 233 
supplementation trial involving resistant starch type 2 (77). 234 
A study evaluating α-diversity through Simpson’s index found it was significantly higher in 235 
the intervention group receiving polydextrose compared with placebo after 21 days (P = 236 
0.014) (88). A trial involving 15 g/d arabinoxylan supplementation reported variable 237 
intervention effects when α-diversity was evaluated using different metrics: α-diversity was 238 
significantly lower compared with placebo when measured through observed species (P = 239 
0.029), but there were no significant differences when assessed by Simpson’s evenness (P = 240 
0.063) (80). 241 
A separate meta-analysis was performed for the three studies reporting α-diversity measured 242 
by total number of observed OTUs (49, 72, 75). Dietary fiber had no effect on α-diversity 243 
compared with placebo/low fiber comparators [MD: -4.37 OTUs (95% CI: -42.92, 34.19), P = 244 
0.82], with no heterogeneity (I2 = 0%). The Chao1 index was used to report α-diversity in two 245 
studies, although there was insufficient data available precluding meta-analysis. Neither trial 246 
reported significant differences between fiber intervention and placebo or low fiber control 247 
(49, 83). A feeding trial comparing wholegrain and refined grain diets found no difference in 248 
α-diversity at end of intervention between the two groups, although the metric used to measure 249 
α-diversity was not reported (79). 250 
Dietary fiber and bacterial abundances 251 
Reporting of bacterial abundances differed across studies. Of the taxa of interest in this review, 252 
abundances of Bifidobacterium spp. (59 studies) and Lactobacillus spp. (28 studies) were most 253 
commonly reported. No studies reported on the abundance of Akkermansia muciniphila. 254 
15 
 
A total of 59 studies including 1896 participants reported the effect of dietary fiber on 255 
Bifidobacterium spp. abundance and of these, 51 trials (1629 participants) reported data in a 256 
form suitable for meta-analysis (53-58, 60, 61, 63-68, 70, 71, 73-76, 81, 82, 84-94, 96-112, 257 
114). Dietary fiber led to a significantly greater Bifidobacterium spp. abundance compared 258 
with placebo/low fiber comparators [SMD: 0.64 (95% CI: 0.42, 0.86), P < 0.00001], albeit 259 
with considerable heterogeneity (I2 = 85%) (Figure 2).  260 
However, subgroup analysis showed fiber interventions delivered through supplements 261 
resulted in a significantly higher Bifidobacterium spp. abundance compared with placebo/low 262 
fiber controls [SMD: 0.75 (95% CI: 0.52, 0.98), P < 0.00001, I2 = 83%], whereas no 263 
differences were found between food interventions and comparators [SMD: 0.20 (95% CI: -264 
0.36, 0.76), P = 0.49, I2 = 88%], although considerable heterogeneity persisted in both 265 
analyses. 266 
Subgroup analysis demonstrated interventions investigating fibers classified as accepted 267 
prebiotics and candidate prebiotics resulted in a significantly higher Bifidobacterium spp. 268 
abundance compared with placebo/low fiber controls [Accepted prebiotic fiber SMD: 0.68 269 
(95% CI: 0.38, 0.98), P < 0.00001, I2 = 81%; Candidate prebiotic fiber SMD: 0.77 (95% CI: 270 
0.30, 1.24), P < 0.00001, I2 = 86%] (Figure 2). However, there was no difference in effect 271 
between the general fiber subgroup compared with comparators [SMD: 0.25 (95% CI: -0.16, 272 
0.65), P = 0.24, I2 = 86%]. This subgroup analysis did not reduce the considerable 273 
heterogeneity across each subgroup. 274 
Subgroup analysis of dose-response showed dietary fiber led to significantly higher 275 
Bifidobacterium spp. abundance compared with placebo/low fiber comparators at all pre-276 
defined dosage [≤5g/d fiber SMD: 0.51 (95% CI: 0.18, 0.84), P = 0.003, I2 = 70%; 5-10g/d 277 
SMD: 0.48 (95% CI: 0.13, 0.83), P = 0.007, I2 = 87% >10g/d SMD: 0.85 (95% CI: 0.45, 1.25), 278 
16 
 
P < 0.00001, I2 =85%]. No differences were found in subgroup analyses of trial design or 279 
microbiota analysis method (Supplemental Table 6). 280 
Eight trials were not included in the meta-analysis. In the supplement trials of accepted 281 
prebiotics, a significantly higher Bifidobacterium spp. abundance was reported following 282 
supplementation involving inulin (115) and human milk oligosaccharides (HMO) (62) 283 
compared with placebo at the end of intervention, while a significant within-group increase 284 
from baseline was detected following 10g/d inulin supplementation (95). In the candidate 285 
prebiotic trial of resistant starch supplementation, Bifidobacterium spp. abundance was 286 
significantly higher in the intervention group compared with placebo at end of intervention 287 
(77). In the supplement studies of general fiber, Bifidobacterium spp. abundance was higher 288 
following after xylo-oligosaccharide supplementation compared with placebo (69) while 289 
manno-oligosaccharides had no effect on Bifidobacterium spp. compared with placebo (113). 290 
The third supplement trial of general fiber (resistant maltodextrin) reported no change in 291 
Bifidobacterium spp. abundance within groups using FISH, although a significant increase 292 
from baseline was reported for the intervention group on qPCR analysis (83). Finally, a food 293 
study comparing intakes of wholegrains to refined grain products found no significant 294 
difference in Bifidobacterium spp. abundance at the end of intervention period (78). 295 
Lactobacillus spp. abundance was measured in 28 studies involving 867 participants. Data 296 
from 24 studies (730 participants) was reported in a form suitable for meta-analysis (52, 55, 297 
56, 60, 63-68, 73, 75, 76, 84, 87, 93, 96, 97, 99, 104, 105, 107, 111, 114). Dietary fiber led to a 298 
significantly greater Lactobacillus spp. abundance compared with placebo/low fiber 299 
comparators [SMD: 0.37 (95% CI: 0.07, 0.68), P = 0.02]. However, heterogeneity was 300 
considerable (I2 = 80%), and was skewed by results from a single outlier study (66) [4.70 (95% 301 
CI: 3.69, 5.70)]. A sensitivity analysis excluding this study produced a more homogenous 302 
study population (I2 = 49%), with a modest impact on the result [SMD: 0.22 (95% CI: 0.03, 303 
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0.41), P = 0.02] (Figure 3). The outlier study (66) was excluded from subsequent subgroup 304 
analyses. 305 
Subgroup analysis demonstrated interventions involving fiber supplements resulted in a 306 
significantly higher Lactobacillus spp. abundance compared with placebo/low fiber controls 307 
while substantially reducing study heterogeneity [SMD: 0.16 (95% CI: 0.01, 0.31), P = 0.04, I2 308 
= 7%]. No significant differences in effect were found between food interventions and 309 
comparators [SMD: 0.35 (95% CI: -0.46, 1.16), P = 0.40, I2 = 84%]. 310 
Subgroup analysis of fiber types showed accepted prebiotic fiber interventions led to a 311 
significantly greater Lactobacillus spp. abundance compared with placebo/low fiber controls 312 
and further reduced heterogeneity [SMD: 0.34 (95% CI: 0.13, 0.55), P = 0.002, I2 = 0%] 313 
(Figure 3). There were no differences in effect in the candidate prebiotic [SMD: -0.06 (95% 314 
CI: -0.29, 0.16), P = 0.58, I2 = 0%] and general fiber [SMD: 0.22 (95% CI: -0.31, 0.75), P = 315 
0.42, I2 = 74%] subgroups when compared with comparators.  316 
Subgroup analysis of analysis method demonstrated dietary fiber led to significantly higher 317 
Lactobacillus spp. abundance compared with placebo/low fiber comparators when enumerated 318 
via culture [SMD: 0.61 (95% CI: 0.13, 1.08), P = 0.01]. There were no significant differences 319 
between intervention and comparator when Lactobacillus spp. was detected using FISH, qPCR 320 
or sequencing (Supplemental Table 6). There were no differences in effect when sub-321 
analyzing by intervention type or dose-response (Supplemental Table 6). 322 
There were four studies that could not be pooled into the meta-analysis. A prebiotic 323 
supplementation trial of HMOs reported no difference in Lactobacillus spp. abundance 324 
between intervention and control groups (62). There was also no significant difference in 325 
Lactobacillus spp. reported in a wholegrain food intervention study compared with controls 326 
(78). Of the two remaining studies, there was higher Lactobacillus spp. abundance following 327 
xylo-oligosaccharide supplementation compared with placebo (69), and significant within-328 
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group increases in Lactobacillus spp. abundance was demonstrated following manno-329 
oligosaccharide supplementation (113).  330 
Abundance of F. prausnitzii was measured in 15 studies investigating 566 participants. 331 
Thirteen studies (519 participants) were able to be meta-analyzed (53, 61, 67, 68, 74, 84, 88, 332 
94, 99-101, 110, 112). There was no difference between dietary fiber compared with 333 
placebo/low fiber comparators for F. prausnitzii abundance [SMD: 0.14 (95% CI: -0.12, 0.39), 334 
P = 0.29], with substantial heterogeneity between studies (I2 = 68%) (Figure 4). Aside from 335 
trial design, no differences with respect to the pre-specified subgroups were found 336 
(Supplemental Table 6). Two studies reporting abundances of F. prausnitzii were unable to 337 
be pooled into the meta-analysis. Both studies measured the relative abundance of F. 338 
prausnitzii and reported only within-group changes, with one study reporting a decrease in 339 
abundance following supplementation of flaxseed mucilage (59), and the other reporting an 340 
increase in abundance following inulin supplementation (50). 341 
Seven studies including 261 participants measured Roseburia spp. abundance. Four studies 342 
(189 participants) were included in the meta-analysis (49, 68, 79, 97). Dietary fiber had no 343 
effect on Roseburia spp. abundance compared with placebo/low fiber comparators [SMD: 0.33 344 
(95% CI: -0.14, 0.80), P = 0.17] although substantial heterogeneity was detected (I2 = 70%) 345 
(Figure 4). Similar results were reported in the studies excluded from meta-analysis. No 346 
between or within-group differences were detected between intervention and placebo groups in 347 
two prebiotic fiber supplement trials (50, 62). A third trial found the relative abundance of 348 
Roseburia spp. was lower following inulin supplementation compared with control at end of 349 
intervention, although significance was not reported (115). 350 
Two studies of 32 participants measured E. hallii abundance. These results could not be 351 
statistically pooled because one study did not report data in a suitable form. One study 352 
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reported no within-group difference in E. hallii abundance (50, 62), the other reported a 353 
significant decrease in E. hallii abundance compared with placebo (49). 354 
E. rectale was measured in three studies including 42 participants. Two studies (30 355 
participants) were suitable for meta-analysis (84, 101). Dietary fiber did not impact on E. 356 
rectale abundance compared with placebo/low fiber comparators [SMD: -0.26 (95% CI: -1.20, 357 
0.67), P = 0.58] and substantial heterogeneity was detected (I2 = 75%) (Figure 4). The study 358 
not eligible for meta-analysis was an inulin supplementation trial which reported no difference 359 
for within-group effects for E. rectale abundance (50). 360 
R. bromii abundance was measured in three studies encompassing 76 participants, of which all 361 
were suitable for meta-analysis (49, 81, 101). Dietary fiber had no effect on R. bromii 362 
abundance compared with placebo/low fiber comparators [SMD: 0.15 (95% CI: -0.15, 0.45), P 363 
= 0.33], with no heterogeneity detected (I2 = 0%) (Figure 4). 364 
Dietary fiber and short-chain fatty acids 365 
A total of 25 studies of 870 participants reported between-group differences in fecal SCFA 366 
concentration following fiber intervention (52, 53, 55, 59, 63, 64, 66-68, 71, 73, 74, 77, 80, 82, 367 
84, 86, 90, 91, 93, 94, 96, 103, 112, 115). Fecal SCFA concentration was determined through 368 
gas-liquid chromatography in all but one study (90) where high-performance liquid 369 
chromatography was used. 370 
Total fecal SCFA concentration was measured in 13 studies encompassing 406 participants 371 
(52, 55, 59, 63, 64, 67, 73, 80, 82, 84, 86, 91, 94). Dietary fiber had no effect on total SCFA 372 
concentration compared with placebo/low fiber comparators [SMD: 0.11 (95% CI: -0.05, 373 
0.27), P = 0.19], with similar intervention effects across studies (I2 = 0%). 374 
Fecal acetate concentration was reported in 18 studies involving 657 participants (52, 53, 63, 375 
66, 71, 74, 77, 80, 82, 84, 86, 90, 91, 93, 94, 96, 103, 112). There was no difference in fecal 376 
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acetate following fiber intervention compared with placebo/low fiber comparators [SMD: 0.28 377 
(95% CI: -0.08, 0.63), P = 0.13] with substantial heterogeneity between studies (I2 = 86). 378 
The effect of fiber intervention on fecal propionate concentration was reported in 19 studies of 379 
677 participants (52, 53, 63, 66, 71, 74, 77, 80, 82, 84, 86, 90, 91, 93, 94, 96, 103, 112, 115). 380 
No differences were found between fecal propionate and comparators [SMD: -0.01 (95% CI: -381 
0.20, 0.22), P = 0.95], with moderate heterogeneity detected (I2 = 61%). 382 
The effect of fiber intervention on fecal butyrate concentration was reported in 20 studies of 383 
712 participants (52, 53, 59, 63, 66, 71, 74, 77, 80, 82, 84, 86, 90, 91, 93, 94, 96, 103, 112, 384 
115). Fecal butyrate was significantly higher following fiber intervention compared with 385 
placebo/low fiber comparators [SMD: 0.24 (95% CI: 0.00, 0.47), P = 0.05], although 386 
considerable heterogeneity was present (I2 = 70%). 387 
Of the studies evaluating differences in fecal SCFA concentration following fiber intervention 388 
compared with placebo/low fiber comparators, 13 studies expressed mean SCFA 389 
concentrations per wet weight of feces (52, 53, 66, 67, 71, 73, 74, 77, 82, 90, 91, 96, 115), 10 390 
studies as dry weight of feces (55, 59, 63, 64, 68, 80, 93, 94, 103, 112), one study as molar 391 
ratio (84), and one study as a combination of wet weight of feces and molar ratio (86). 392 
Additional subgroup analyses were performed to compare differences in fecal SCFA 393 
concentrations when expressed as wet weight compared with dry weight (Supplemental 394 
Table 7). Fiber intervention led to significantly higher fecal concentrations of total SCFA, 395 
acetate and butyrate compared with comparators when expressed per wet weight of feces. 396 
However, there were no significant differences when mean SCFA concentrations were 397 
expressed per dry weight of feces. Study heterogeneity was considerably greater for fecal 398 
acetate and butyrate, but not total fecal SCFA concentrations when expressed as wet compared 399 
with dry wet of feces. There were no differences in effect based on analysis method for fecal 400 
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propionate concentrations, although heterogeneity was greater when results were expressed per 401 
wet weight of feces (Supplemental Table 7). 402 
Differences in intervention effects based on trial design 403 
There were differences in intervention effects in subgroup analyses depending upon trial 404 
design. Dietary fiber led to significantly lower α-diversity compared with placebo/low fiber 405 
comparators in crossover design trials, where α-diversity was reported using Shannon diversity 406 
index [MD: -0.10 (95% CI: -0.19, -0.01), P = 0.03], while there was no difference in α-407 
diversity in parallel design trials [MD: -0.03 (95% CI: -0.57, 0.51), P = 0.91] (Supplemental 408 
Table 6). The presence and duration of washout periods were inconsistent across the three 409 
crossover trials included this analysis. One study did not include a wash out period (84), and 410 
wash out periods lasted 14 (75) and 21 days (88) in the other two. Regarding bacterial 411 
abundances however, intervention effects were significant in parallel trials but not in crossover 412 
trials for Lactobacillus and Roseburia spp. and F. prausnitzii, but not for Bifidobacterium spp. 413 
(Supplemental Table 6). Statistical heterogeneity was lower in crossover trials compared with 414 
parallel trials for α-diversity reported using Shannon diversity index, Bifidobacterium and 415 
Lactobacillus spp., as well as F. prausnitzii, but there was no difference in statistical 416 
heterogeneity for Roseburia spp. (Supplemental Table 6). 417 
Risk of bias 418 
The risk of bias was low-to-moderate across the 64 included studies (Supplemental Figure 1). 419 
Selection bias was unclear in most studies. Random sequence generation and allocation 420 
concealment were adequately described by 26% (59-62, 70-72, 77, 79, 80, 84, 86, 94, 103, 421 
113-115) and 16% (59, 61, 62, 70, 77, 79, 80, 86, 94, 115) of studies, respectively. There was 422 
low risk of bias across included studies regarding performance and detection bias, as most 423 
trials investigated objective outcomes and incorporated a double-blind design. Attrition bias 424 
was adequately addressed by only 41% (54-58, 62, 67, 69, 71, 74-76, 79, 82, 86-89, 92, 93, 98, 425 
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99, 105, 107, 108, 110) of the included studies. Selective reporting was unclear in the majority 426 
of studies. Published protocols or clinical registrations were reported by only 26% (59, 61, 68-427 
70, 75, 77-80, 86, 97, 100-102, 110, 115) of included studies. Bias related to control of dietary 428 
intake was unclear in half of included studies (55%) (54, 56-60, 62, 64-67, 71, 72, 74, 78, 80, 429 
81, 83, 85-93, 96, 98, 102, 103, 105, 108, 110, 115), while even fewer studies were judged to 430 
have a low risk of bias regarding dietary advice and assessment of dietary compliance (33%) 431 
(52, 55, 63, 68, 69, 73, 75, 76, 79, 82, 84, 94, 97, 99, 104, 106, 107, 111-114). Furthermore, 432 
13% (53, 61, 70, 77, 95, 100, 101, 109) of studies did not provide dietary advice or assess 433 
intake, and were judged to have a high risk of bias relating to the potential influence of 434 
background dietary intake. 435 
Reporting bias 436 
Funnel plots were generated for abundances of Bifidobacterium spp.; Lactobacillus spp.; F. 437 
prausnitzii; and total SCFA; acetate; propionate; and butyrate concentrations. Visual 438 
inspection found no evidence of funnel plot asymmetry, indicating reporting bias was unlikely 439 
(Supplemental Figures 2-7).  440 
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DISCUSSION 441 
This systematic review and meta-analysis found dietary fiber intervention had no effect on the 442 
diversity of the gut microbiota but did increase abundance of Bifidobacterium and 443 
Lactobacillus spp. as well as fecal butyrate concentration in healthy adults.  444 
The lack of effect on α-diversity of the gut microbiota found in this review is similar to other 445 
dietary interventions documented in the literature. For instance, controlled feeding studies 446 
lasting four days to three weeks found that despite significant changes to fiber intake, there 447 
was no effect on microbial diversity (35-37). These findings suggest that short-term dietary 448 
interventions are unlikely to facilitate changes in the α-diversity of the gut microbiota. Indeed, 449 
study design is likely important, as subgroup analysis demonstrated different effects between 450 
crossover and parallel trials. The lower α-diversity between fiber and control groups in 451 
crossover trials may be related to a lack of or insufficient wash-out between interventions, as 452 
well as potential differences in the microbiota and habitual diet of individuals at baseline. 453 
These null findings are in contrast to the findings from observational studies that report a 454 
correlation between fiber intakes in habitual diet and diversity of the gut microbiota, for 455 
example in studies comparing agrarian dietary habits with Western populations (38, 39). 456 
Interestingly, a positive correlation has also been reported between dietary diversity and 457 
microbiota diversity (116). Taken together, long term dietary diversity as opposed to changes 458 
in isolated nutrients or foods over a short period of time may be a stronger driver of microbial 459 
diversity. It must also be noted that the stability of the gut microbiota, as well as the 460 
abundances and metabolites of the individual members of the microbial community, also 461 
contribute to maintaining an ecosystem that promotes health (117, 118). Therefore, the totality 462 
of findings here, including that microbial diversity was not compromised, support the 463 
favorable effects of dietary fiber on the gut microbiota. 464 
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In regard to particular bacterial groups, this review demonstrated dietary fiber interventions 465 
involving accepted prebiotic fibers led to higher abundance of Bifidobacterium and 466 
Lactobacillus species. These results support the selectivity criteria of the prebiotic concept, 467 
where the host microorganisms selectively utilize the prebiotic fibers as substrates, which may 468 
confer health benefits to the host (32). However, candidate prebiotic interventions produced 469 
different effects on the abundance of these two genera, with significant effects demonstrated 470 
for Bifidobacterium but not Lactobacillus species. This may represent differences in substrate 471 
preferences between the two genera, where Bifidobacterium spp. may be less discriminating 472 
than Lactobacillus spp. regarding fermentation substrates (119, 120). Conversely, fibers not 473 
classified as accepted or candidate prebiotics, here termed general fibers, did not impact the 474 
abundance of these taxa. This may be due to the heterogeneity of the general fibers, including 475 
their degree of polymerization, viscosity and fermentability, whereas accepted and candidate 476 
prebiotic fibers are mostly highly fermentable oligosaccharides (29, 30).  477 
Subgroup analysis separating the effect of food vs supplement interventions showed food 478 
interventions had no effect on Bifidobacterium and Lactobacillus species. This result may be 479 
attributed to a lack of statistical power, due to the food interventions comprising a relatively 480 
small number of low sample size studies (10 studies, 301 participants; 4 studies, 127 481 
participants). It must also be noted that most of the trials employing food interventions 482 
supplemented with grain and cereal foods to increase fiber intake (71, 78, 79, 82, 85, 89, 96, 483 
98, 104). Therefore, the food interventions evaluated may be more representative of grains and 484 
cereals per se rather than a diverse range of fibrous foods. 485 
Interestingly, there were no differences in the effect of dietary fiber interventions on 486 
Bifidobacterium spp. abundance with varying doses of fiber. Dietary fiber intervention led to 487 
an effect at all levels of consumption in subgroup analysis (≤5g, 5-10g, >10g) with no 488 
discernible gradient in effectiveness, suggesting fewer than 5 grams of dietary fiber is 489 
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sufficient. This may represent a potential limit to the amount of fiber that can be fermented by 490 
Bifidobacterium species. The lack of a dose-response effect may also be attributed to the 491 
percentage increase in fiber intake from baseline rather than the intervention dose, which was 492 
unable to be accounted for in this review due to the inconsistent reporting of baseline values 493 
across included studies. This requires further clarification but lower dose supplementation may 494 
be advantageous in patients who experience GI symptoms with higher fiber loads. 495 
There was more variability in intervention effects for abundances of Bifidobacterium spp. (I2 = 496 
85%) compared with Lactobacillus spp. (I2 = 49%). While this may be related to differences in 497 
the accuracy of techniques used to determine specific bacterial abundances (121, 122), there 498 
were no differences in effect based on analysis method for Bifidobacterium species. Another 499 
plausible explanation is the differences in nutrient requirements of these taxa as discussed 500 
previously. Furthermore, ‘responder and non-responder’ effects for Bifidobacterium spp. 501 
abundance, which have been shown previously (97, 123, 124), may be impacted by individual 502 
host factors, such as differences in baseline abundances (124), or the presence/absence of 503 
specific strains of Bifidobacterium able to utilize the particular fiber under investigation. 504 
There were differences in intervention effects based on trial design, with parallel design 505 
studies demonstrating stronger intervention effects and greater statistical heterogeneity 506 
compared with crossover design studies for several outcomes. This may in part be due to inter-507 
individual differences in microbiota composition as well as carry-over effects from a lack of or 508 
insufficient wash-out periods in the crossover studies as discussed previously. 509 
There was no effect of dietary fiber interventions on abundance of other commonly measured 510 
bacterial groups (e.g. F. prausnitzii), suggesting these species may be stimulated by dietary 511 
components other than fiber, such as polyols and polyphenols (125). However, the number of 512 
studies evaluating species of other bacterial groups was small, and therefore further studies are 513 
needed to investigate the effect of fiber and other dietary components on these groups. 514 
26 
 
The higher fecal concentration of butyrate following fiber intervention highlights the ability of 515 
dietary fiber to beneficially modulate the metabolic outputs of the gut microbiota. This is 516 
likely due to cross-feeding interactions between butyrate producers with Bifidobacterium and 517 
Lactobacillus species, which are noted lactate and acetate producers (25, 120, 126). As the 518 
preferred energy source for colonic epithelial cells, butyrate is a microbial by-product that is of 519 
particular interest to host health, exhibiting a wide spectrum of positive effects, such as 520 
inhibiting colonic carcinogenesis and ameliorating mucosal inflammation (31, 127, 128). 521 
However, it is acknowledged that the variability in the reporting of SCFA results may limit the 522 
applicability of these findings, particularly when considering the variance in results when 523 
expressed as wet compared with dry weight of feces. 524 
This study is the first systematic review and meta-analysis to assess the effect of dietary fiber 525 
intervention on gut microbiota composition. Major strengths of this study include its robust 526 
design, comprehensive search strategies, and the use of two independent reviewers. 527 
It is acknowledged this study has some limitations. Firstly, there were only a limited number 528 
of studies reporting the primary outcome of α-diversity, and a small proportion presenting data 529 
using the same diversity indices. Secondly, baseline fiber intake was not able to be accounted 530 
for due to the paucity of reporting by included studies. Furthermore, included studies sampled 531 
feces as a surrogate for gut microbiota profile, and although feces are a common sampling 532 
route, the microbial composition of feces differs from the mucosal microbiota (10, 11), which 533 
is in closer contact with the host and may be more important when considering the relationship 534 
between microbiota and disease pathophysiology or outcomes. Finally, the limited number of 535 
taxa assessed in the review may not convey the overall effect elicited by dietary fiber 536 
intervention on gut microbiota composition and metabolic outputs, although the selection of 537 
taxa was guided by the available literature. Thus, the taxa selected may be more representative 538 
of the scope of research in the field to date, rather than a limitation of the review. 539 
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Dietary fiber intervention leads to a higher abundance of fecal Bifidobacterium and 540 
Lactobacillus spp., as well as higher fecal concentration of butyrate compared with 541 
placebo/low fiber comparators. Accepted prebiotic fibers had an effect on the abundances of 542 
both Bifidobacterium and Lactobacillus spp. while candidate prebiotic fibers had an effect on 543 
Bifidobacterium spp. abundance but not Lactobacillus species. General fibers appear to have a 544 
limited effect on gut microbiota composition. Although the diversity of the gut microbiota, 545 
abundances of other commonly measured bacterial groups and concentration of other fecal 546 
SCFAs were not significantly different compared with controls following dietary fiber 547 
intervention, it is worth noting that a short-term increase in fiber intake does not appear to be 548 
rate-limiting to these outcomes. These results further support the favorable effects of dietary 549 
fiber and contribute to our understanding of its effect on the gut microbiota. 550 
Future RCTs investigating the effect of fiber on the gut microbiota should adjust for 551 
participants’ baseline microbiota composition and dietary characteristics as well as controlling 552 
for dietary intake in order to determine the precise effect of dietary fiber. Scope may also need 553 
to be broadened to evaluate taxa than that considered here, including the eukaryote (e.g. fungi) 554 
members of the gut microbiota. Additionally, longer duration studies are needed to better 555 
assess the chronic effect of fiber on microbiota diversity.  556 
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Table 1: Statistical analysis for the outcomes reported in ≥2 randomized controlled trials and included in the meta-analysis.  
      Results Heterogeneity 
Outcomes No. of studies in meta-
analysis (references) 
n1 Meta-analysis overall estimate 
(95% CI) 
P Chi-
square 
test 
P I2 (%) 
Shannon Diversity 
Index 
6 (64, 72, 75, 80, 84, 88) 127 MD: -0.06 (95% CI: -0.25; 0.12) 0.48 10.73 0.06 53 
Total number of 
observed OTUs 
3 (72, 75, 84) 53 MD: -4.37 (95% CI: -42.92; 34.19) 0.82 0.07 0.97 0 
Bifidobacterium spp. 51 (52-58, 60, 61, 63-68, 
70-76, 82, 84-94, 96-112, 
114) 
1629 SMD: 0.64 (95% CI: 0.42; 0.86) <0.00001 327.93 <0.00001 85 
Lactobacillus spp.2 23 (52, 55, 56, 60, 63-65, 
67, 68, 73, 75, 76, 84, 87, 
93, 96, 97, 99, 104, 105, 
107, 111, 114) 
670 SMD: 0.22 (95% CI: 0.03; 0.41) 0.02 42.8 0.005 49 
Faecalibacterium 
prausnitzii 
13 (53, 61, 67, 68, 74, 
84, 88, 94, 99-101, 110, 
112) 
519 SMD: 0.14 (95% CI: -0.12; 0.39) 0.29 37.53 0.0002 68 
Roseburia spp. 4 (68, 79, 84, 97) 189 SMD: 0.33 (95% CI: -0.14; 0.80) 0.17 10.16 0.02 70 
Eubacterium rectale 2 (84, 101) 30 SMD: -0.26 (95% CI: -1.20; 0.67) 0.58 3.94 0.05 75 
Ruminococcus bromii 3 (81, 84, 101) 76 SMD: 0.15 (95% CI: -0.15; 0.45) 0.33 1.1 0.58 0 
Total SCFA 13 (52, 55, 59, 63, 64, 
67, 73, 80, 82, 84, 86, 91, 
94) 
406 SMD: 0.11 (95% CI: -0.05; 0.27) 0.19 6.46 0.89 0 
Acetate  18 (52, 53, 63, 66, 71, 
74, 77, 80, 82, 84, 86, 90, 
91, 93, 94, 96, 103, 112) 
657 SMD: 0.28 (95% CI: -0.08; 0.63) 0.13 119.36 <0.00001 86 
Propionate  19 (52, 53, 63, 66, 71, 677 SMD: 0.01 (95% CI: -0.20; 0.22) 0.95 46.23 0.0003 61 
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      Results Heterogeneity 
Outcomes No. of studies in meta-
analysis (references) 
n1 Meta-analysis overall estimate 
(95% CI) 
P Chi-
square 
test 
P I2 (%) 
74, 77, 80, 82, 84, 86, 90, 
91, 93, 94, 96, 103, 112, 
115) 
Butyrate  20 (52, 53, 59, 63, 66, 
71, 74, 77, 80, 82, 84, 86, 
90, 91, 93, 94, 96, 103, 
112, 115) 
712 SMD: 0.24 (95% CI: 0.00; 0.47) 0.05 64.21 <0.00001 70 
 
Data was meta-analyzed using a random-effects model and presented as MDs or SMDs as appropriate. Statistical heterogeneity was assessed 
using the chi-square test and quantified using the I2 statistic. 1 Number of participants in meta-analysis. 2 Results from outlier study excluded 
from this meta-analysis. Abbreviations: MD, Mean difference; OTU, Operational taxonomic unit; SCFA, Short chain fatty acid; SMD, 
Standardized mean difference. 
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Table 2: Characteristics of randomized controlled trials of fiber supplementation comparing dietary fiber with placebo or low fiber comparators 
in healthy adults 
 Participants Interventions RCT Design 
Study n; age1; % F Fiber, daily 
dose  
Preb
iotic 
Comparator; 
daily dose  
Compli
ance2 
Design Duration 
(days) 
Run 
in  
Wash 
out  
Analysis 
Abell 2008 
(81) 
46; 25-66; 
65% 
RS, 22 g C RS, 1 g Y Cross-
over 
28 Y Y qPCR 
Alfa 2017 
(77) 
84; 32-96; 
42% 
RS2, 21 g C Corn starch, 21 g  Y Parallel 72 Y N Illumina 
Alles 1999 
(52) 
27.4; 40.4; 
45% 
TOS, 15 g A Glucose & 
lactose mix, 15 g 
Y Parallel 21 Y N Culture 
Baer 2014 
(83) 
14; 47; 9% Resistant 
maltodextrin, 50 
g 
C Maltodextrin, 50 
g  
Y Cross-
over 
21 N Y 454 
Pyrosequencing
; DGGE; FISH; 
qPCR 
Beards 
2010 (53) 
30; 333; 
66%3 
PDX; RS, 45.6 g C Maltilol, 45.6 g N Parallel 44 N N FISH 
Blaedel 
2016 (115) 
21; 23-45; 
100% 
Inulin, 15 g A Placebo Y Cross-
over 
21 N Y Illumina 
Boler 2011 
(84); 
Hooda 
2012 (49)4 
21; 21-28; 
0% 
PDX5; Soluble 
maize fiber, 21 g 
C Placebo N Cross-
over 
21 N N qPCR; 
Pyrosequen-
cing4 
Bouhnik 
1996 (54) 
10; 22-39; 
50% 
SC-FOS, 12.5 g A Saccharose, 10 g N Parallel 12 Y Y Culture 
Bouhnik 
1999 (58) 
8; 29.6; 55% SC-FOS, 20 g A Saccharose, 20 g N Parallel 7 N N Culture 
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 Participants Interventions RCT Design 
Study n; age1; % F Fiber, daily 
dose  
Preb
iotic 
Comparator; 
daily dose  
Compli
ance2 
Design Duration 
(days) 
Run 
in  
Wash 
out  
Analysis 
Bouhnik 
2004 (57) 
64; 303; 
55%3 
SC-FOS5; 
GOS5; Isomalto-
OS; Inulin5; RS; 
Soybean-OS, 10 
g  
A Sucrose & 
maltodextrin 
mix, 10 g 
N Parallel 7 Y N Culture 
Bouhnik 
2006 (56) 
40; 29; 55% SC-FOS 
(Actilight), 10 g 
A Sucrose & 
maltodextrin 
mix, 10 g 
N Parallel 7 Y N Culture 
Bouhnik 
2007 (55) 
39; 33.9; NR Inulin, 5 g A Sucrose & 
maltodextrin 
mix, 5 g 
N Parallel 28 Y Y Culture 
Brahe 2015 
(59) 
35; 59.63; 
100% 
Flaxseed 
mucilage, 10 g 
G Placebo Y Parallel 42 N N Quantitative 
metagenomics 
Calame 
2008 (60) 
16; 30.9; NR Arabic gum, 40 g G Placebo Y Parallel 28 N N qPCR 
Clarke 
2016 (86) 
30; 27; 57% Beta 2-1 fructan, 
15 g 
A Maltodextrin, 15 
g 
Y Cross-
over 
28 N Y qPCR 
Cloetens 
2010 (87) 
20; 24; 70% AXOS, 10 g C Maltodextrin, 20 
g 
N Cross-
over 
21 N Y qPCR 
Costabile 
2010 (90) 
31; 25; 56% Very long chain 
inulin, 10 g 
A Maltodextrin, 10 
g 
N Cross-
over 
21 N Y FISH 
Costabile 
2012 (88) 
31; 33; 52% PDX, 8 g C Maltodextrin, 8 g N Cross-
over 
21 N Y DGGE; FISH 
Damen 
2012 (91) 
27; 25; 63% AXOS, 2.14 g C Placebo Y Cross-
over 
21 Y Y FISH 
Depeint 
2008 (92) 
30; 36.3; 
60% 
Beta-GOS, 7 g A Sucrose, 7 g N Cross-
over 
7 Y Y FISH 
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 Participants Interventions RCT Design 
Study n; age1; % F Fiber, daily 
dose  
Preb
iotic 
Comparator; 
daily dose  
Compli
ance2 
Design Duration 
(days) 
Run 
in  
Wash 
out  
Analysis 
Dewulf 
2013 (61) 
30; 47.5; 
100% 
Inulin-type 
fructan (Synergy 
1), 16 g 
A Maltodextrin, 16 
g 
N Parallel Reported 
as 3 
months 
N N qPCR; 
Phylogenetic 
microarray 
Elison 
2016 (62) 
40; 22-57; 
52% 
HMO6: 2′-O-
fucosyllactose 
(2'FL); lacto-N-
neotetraose 
(LNnT); Mixture 
(2:1 mixture of 
2'FL + LNnT), 
20 g 
A Glucose, 2 g Y Parallel 14 Y N Illumina  
Fastinger 
2008 (63) 
25; 26.7; 
50% 
Resistant 
maltodextrin, 15 
g 
C Maltodextrin, 15 
g 
N Parallel 21 Y Y qPCR 
Fernando 
2010 (93) 
12; 25.6; 
42% 
Raffinose, 5 g G Placebo N Cross-
over 
21 N N qPCR; T-RLFP 
Finegold 
2014 (64) 
16; 21-493; 
66%3 
XOS, 2.8 g C Maltodextrin, 2.8 
g 
N Parallel 56 Y Y Pyrosequencing 
Francois 
2012 (94) 
52; 42; 48% Wheat bran 
extract, 10 g 
G Placebo N Cross-
over 
21 Y Y FISH 
Fuller 2007 
(95); 
Ramirez-
Farias 
2009 (50)4 
12; 38.1; 
75% 
Inulin, 10 g A Nil Y Cross-
over 
16 N N qPCR 
Gopal 2003 
(65) 
19; 20-603; 
44%3 
GOS, 2.4 g A Placebo Y Parallel 28 Y Y Culture 
Holscher 
2015 (97) 
29; 27; 52% Agave inulin, 7.5 
g 
A Placebo N Cross-
over 
21 Y Y Illumina  
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 Participants Interventions RCT Design 
Study n; age1; % F Fiber, daily 
dose  
Preb
iotic 
Comparator; 
daily dose  
Compli
ance2 
Design Duration 
(days) 
Run 
in  
Wash 
out  
Analysis 
Jie 2000 
(66) 
30; 29.9; 
45% 
PDX, 12 g C Nil N Parallel 28 Y N Culture 
Kleesen 
2007 (67) 
45; 23.5; 
55% 
Inulin6: Chicory 
inulin; Jerusalem 
artichoke inulin, 
15.4 g 
A Placebo N Parallel 21 Y N Culture; FISH 
Lecerf 
2012 (68) 
59; 20.1; 
57% 
XOS5; Inulin-
XOS mix, 6.64 g 
C Wheat dextrin, 
6.64 g 
N Parallel 28 N N qPCR 
Lin 2016 
(69) 
20; 24.2; 
80% 
XOS, 1.2 g C Placebo N Parallel 42 Y Y Culture 
Lomax 
2012 (70) 
43; 55; 74% Beta 2-1 fructan, 
8 g 
A Maltodextrin, 8 g Y Parallel 28 Y N FISH 
Maki 2012 
(99) 
55; 35.13; 
54%3 
AXOS, 2.4 g C Placebo N Cross-
over 
21 N Y FISH 
Maneerat 
2013 (100) 
35; 67.43; 
53%3 
GOS, 8 g A Maltodextrin, 8 g N Cross-
over 
21 N Y FISH 
Martinez 
2010 (101) 
10; 23-38; 
50% 
RS6: RS2; RS4, 
33.2 g 
C Native wheat 
starch, 33.2 g 
N Cross-
over 
21 Y Y Pyrosequencing 
Pallav 
2014 (72) 
14; 31.43; 
65% 
Polysaccharidepe
ptide (I'm-
Yunity), 3.6 g 
G Nil N Parallel 14 N N Pyrosequencing 
Pasman 
2006 (73) 
29; 34.1; 0% Nutriose FB 
(dextrin), 45 g 
A Maltodextrin, 
22.5 g 
Y Parallel 35 Y N Culture 
Petry 2012 
(102) 
32; 18-40; 
100% 
Inulin, 20 g A Maltodextrin, 20 
g 
N Cross-
over 
28 N Y qPCR 
Ramnani 
2010 (74) 
66; 32.9; 
50% 
Inulin, 5 g A Placebo Y Parallel 21 Y Y FISH 
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 Participants Interventions RCT Design 
Study n; age1; % F Fiber, daily 
dose  
Preb
iotic 
Comparator; 
daily dose  
Compli
ance2 
Design Duration 
(days) 
Run 
in  
Wash 
out  
Analysis 
Ramnani 
2015 (103) 
38; 35.13; 
50% 
Agave inulin, 5 g A Maltodextrin, 5 g Y Cross-
over 
21 Y Y FISH 
Salden 
2017 (80) 
27; 48; 48% Arabinoxylans, 
15 g 
G Maltodextrin, 15 
g 
Y Parallel 42 N N Illumina 
Slavin 
2011 (105) 
10; 27-493; 
0% 
Chicory inulin, 
20 g 
A Placebo Y Cross-
over 
21 N N Culture 
Ten 
Bruggenca
te 2006 
(107) 
29; 22.7; 0% FOS, 20 g A Sucrose, 6 g Y Cross-
over 
14 N Y qPCR 
Tuohy 
2011 (108) 
NR; NR; 
55% 
Mix:(FOS & 
PHGG), 10 g 
Mix Placebo Y Cross-
over 
21 N N FISH 
Vulevic 
2008 (109) 
41; 69.33; 
64%3 
GOS (Bimuno), 
5.5 g 
A Maltodextrin, 5.5 
g 
Y Cross-
over 
70 N Y FISH 
Vulevic 
2015 (110) 
40; 70.4; 
62% 
GOS (Bimuno), 
5.5 g 
A Maltodextrin, 5.5 
g 
Y Cross-
over 
70 N Y FISH 
Walton 
2010 (113) 
31; 21; 58% MOS, 5 g C Placebo Y Cross-
over 
21 N Y FISH 
Walton 
2012 (111) 
37; 58.93; 
57%3 
GOS, 8 g A Placebo N Cross-
over 
21 Y Y qPCR 
Walton 
2012 (112) 
40; 31.43; 
60%3 
AXOS, 2.2 g C Placebo Y Cross-
over 
21 Y Y FISH 
Wu 2011 
(76) 
15; 40.6; 
93% 
Konjac 
glucomannan, 
4.5 g 
G Nil N Parallel 28 N N FISH 
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1 Age expressed as mean years; age range provided where means were not obtainable. 2 Compliance to intervention; assessed by primary study. 3 
Refers to randomized population rather than actual population. Compliance to intervention; assessed by primary study. 4 Secondary publication 
reporting additional outcomes from the primary study. 5 Refers to analyzed intervention arm with the highest prebiotic classification (accepted 
prebiotic fiber > candidate prebiotic fiber > general fiber) selected for fiber type subgroup analysis. 6 Refers to intervention fibers that have been 
pooled together for meta-analyses. Abbreviations: A; Accepted prebiotic fiber; AXOS; Arabinoxylan-oligosaccharide; C; Candidate prebiotic 
fiber; DGGE; Denaturing gradient gel electrophoresis; FISH; Fluorescent in situ hybridization; G; General fiber; GOS; Galacto-oligosaccharide; 
HMO; Human milk oligosaccharide; MOS; Manno-oligosaccharide; NR; Not reported by study; OS; Oligosaccharide; PDX; Polydextrose; 
PHGG; Partially hydrolyzed guar gum; qPCR; Quantitative polymerase chain reaction; RS; Resistant starch; RS2; Resistant starch 2; RS4; 
Resistant starch 4; SC-FOS; Short chain fructo-oligosaccharide; TOS; Trans-galacto-oligosaccharide; XOS; Xylo-oligosaccharide. 
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Table 3: Characteristics of randomized controlled trials of food interventions comparing dietary fiber with low fiber comparators in healthy 
adults 
 Participants Interventions RCT Design 
Study n; age1; % F Interventi
on 
Comparat
or 
Daily 
fiber 
difference 
Study 
diet2 
Compl-
iance3 
Design Duration 
(days) 
Run in  Wash 
out  
Analysis 
Ampatzogl
ou 2008 
(82) 
33; 48.8; 
64% 
WG diet RG diet 10 g N Y Cross-
over 
14 Y Y FISH 
Carvalho-
Wells 2010 
(85) 
32; 31.6; 
66% 
WG  
cereal 
Non-WG 
cereal 
6.5 g N N Cross-
over 
21 Y Y FISH 
Cooper 
2017 (78) 
46; 25.8; 
46% 
WG 
market 
basket 
RG market 
basket 
5 g N Y Parallel 42 N N Illumina 
Costabile 
2008 (89) 
31; 25; 52% WG cereal Wheat 
bran cereal 
7.4 g N N Cross-
over 
21 Y Y FISH 
Grasten 
2007 (96) 
14; 59.74; 
100% 
Rye bread White 
wheat 
bread 
19 g N Y Cross-
over 
56 Y Y Culture 
Jenkins 
1999 (98) 
24; 33; 50% Wheat 
bran 
Wheat 
flour 
19 g N Y Cross-
over 
14 N Y Culture 
Karl 2017 
(79); 
Vanegas 
2017 (51)5 
81; 40-654; 
60% 
WG diet RG diet 8 g Y Y Parallel 42 Y N Illumina 
Nemoto 
2011 (71) 
36; 22-67; 
63% 
Fermented 
brown rice 
"Non-
functional 
food" 
4.62 g N Y Parallel 14 N N Culture 
Ross 2011 17; 35; 65% WG diet RG diet 13 g Y Y Cross- 14 Y Y qPCR 
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 Participants Interventions RCT Design 
Study n; age1; % F Interventi
on 
Comparat
or 
Daily 
fiber 
difference 
Study 
diet2 
Compl-
iance3 
Design Duration 
(days) 
Run in  Wash 
out  
Analysis 
(104) over 
Smith 2006 
(106) 
18; 42.8; 0% Lupin 
kernal 
fiber diet 
Control 
diet 
22 g Y N Cross-
over 
28 N Y FISH 
Tap 2015 
(75) 
19; 19-25; 
53% 
High fiber 
diet 
Low fiber 
diet 
30 g Y Y Cross-
over 
5 N Y 454 
Pyroseque
ncing 
Zeng 2015 
(114) 
77; 63.4; 
70% 
Whole 
cereal 
legume 
diet 
Control 
diet 
14.5 g Y Y Parallel 90 N N Culture 
 
1 Age expressed as mean years; age range provided where means were not obtainable. 2 Whether the participant’s entire diet was provided by the 
study. 3 Compliance to intervention; assessed by primary study. 4 Refers to randomized population rather than actual population. 5 Secondary 
publication reporting additional outcomes from the primary study. Abbreviations: FISH; Fluorescent in situ hybridization; qPCR; Quantitative 
polymerase chain reaction; RG; Refined grain; WG; Whole grain. 
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Figure 1: Flow diagram of studies evaluated in the systematic review. 
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Figure 2: Forest plot of randomized controlled trials in healthy adults comparing dietary fiber 
with placebo/low fiber comparators. Studies are sub-grouped by fiber type, with the overall 
effect included at the bottom. Data are presented as means and SDs of Bifidobacterium spp. 
abundance at end of intervention. Effects of trials are presented as weights (percentages) and 
SMD (95% CI). CI, confidence interval; IV, inverse variance; SD, standard deviation; SMD, 
standardized mean difference. 
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Figure 3: Forest plot of randomized controlled trials in healthy adults comparing dietary fiber 
with placebo/low fiber comparators. Studies are sub-grouped by fiber type, with the overall 
effect included at the bottom. Data are presented as means and SDs of Lactobacillus spp. 
abundance at end of intervention are reported for trials. Effects of trials are presented as 
weights (percentages) and SMD (95% CI). CI, confidence interval; IV, inverse variance; SD, 
standard deviation; SMD, standardized mean difference. 
 
  
 Page 61 of 87 
 
 
 
Figure 4: Forest plot of randomized controlled trials in healthy adults comparing dietary fiber 
with placebo/low fiber comparators. The means and SDs of Faecalibacterium prausnitzii, 
Roseburia spp., Eubacterium rectale and Ruminococcus bromii abundance at end of 
intervention are reported for trials. Effects of trials are presented as weights (percentages) and 
SMD (95% CI). CI, confidence interval; IV, inverse variance; SD, standard deviation; SMD, 
standardized mean difference. 
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Supplemental Table 1: Search algorithm: MEDLINE via OVID 
1. exp Dietary Fiber/  
2. roughage*.tw.  
3. exp Prebiotics/  
4. prebiotic*.tw.  
5. (carbohydrate adj2 polymer*).tw.  
6. ((non-starch or nonstarch) adj (poly-saccharide* or 
polysaccharide*)).tw.  
7. 1 or 2 or 3 or 4 or 5 or 6  
8. Diet/  
9. diet*.tw.  
10. consum*.tw.  
11. eat*.tw.  
12. food*.tw.  
13. nutri*.tw.  
14. 8 or 9 or 10 or 11 or 12 or 13  
15. Agar/  
16. agar*.tw.  
17. Alginates/  
18. alginate*.tw.  
19. (alginic adj2 acid*).tw. 
20. Carrageenan/  
21. carrageen*.tw.  
22. exp Cellulose/  
23. cellulose*.tw.  
24. exp Chitin/  
25. chitin*.tw.  
26. hemicellulose*.tw.  
27. hexosan*.tw.  
28. Lignin/  
29. lignin*.tw.  
30. Pectins/  
31. pectin*.tw.  
32. pentosan*.tw.  
33. polydextrose*.tw.  
34. polyuronide*.tw.  
35. Raffinose/  
36. raffinose*.tw.  
37. xanthan*.tw.  
38. Xylose/  
39. xylose*.tw.  
40. exp Galactans/  
41. galactan*.tw.  
42. (galactooligosaccharide* or galacto-
oligosaccharide* or gos or tos).tw.  
43. exp Fructans/  
44. fructan*.tw.  
45. (fructooligosaccharide* or fructo-
oligosaccharide* or fos or oligofructose or oligo-
fructose).tw. 
46. exp Inulin/  
47. Inulin*.tw.  
48. (gentiooligosaccharide* or gentio-
oligosaccharide*).tw.  
49. (isomalto oligosaccharide* or isomalto-
oligosaccharide* or imo).tw.  
50. (mannanooligosaccharide* or mannano-
oligosaccharide*).tw.  
51. (N-acetylchitooligosaccharide* or N-acetylchito-
oligosaccharide*).tw. 
52. (pectic oligosaccharide* or pectic-
oligosaccharide*).tw. 
53. (resistant starch* or resistant-starch*).tw.
  
54. (soybean oligosaccharide* or soybean-
oligosaccharide*).tw.  
55. (xylooligosaccharide* or xylo-
oligosaccharide*).tw.  
56. exp Oligosaccharides/ 
57. Oligosaccharide*.tw. 
58. (fiber* or fiber* or high-fiber* or high-fiber*).tw. 
59. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 
or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 
or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 
or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 
or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58
  
60. 14 and 59 
61. 7 or 60 
62. exp Gastrointestinal Microbiome/ 
63. (microbiota or microbiome).tw. 
64. bifido*.tw. 
65. lactobacill*.tw. 
66. 62 or 63 or 64 or 65  
67. (faecal or fecal).tw.  
68. (bacteri* or flora).tw. 
69. 67 and 68  
70. exp Dysbiosis/ 
71. 66 or 69 or 70 
72. 61 and 71  
73. ((randomized controlled trial or controlled 
clinical trial).pt. or randomized.ab. or randomised.ab. 
or placebo.ab. or drug therapy.fs. or randomly.ab. or 
trial.ab. or groups.ab.) not (exp animals/ not 
humans.sh.) 
74. 72 and 73 
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Supplemental Table 2: Search algorithm: EMBASE 
1. exp Dietary Fiber/ 
2. roughage*.tw. 
3. exp Prebiotics/ 
4. prebiotic*.tw. 
5. (carbohydrate adj2 polymer*).tw. 
6. ((non-starch or nonstarch) adj (poly-saccharide* or 
polysaccharide*)).tw. 
7. 1 or 2 or 3 or 4 or 5 or 6 
8. Diet/  
9. diet*.tw. 
10. consum*.tw. 
11. eat*.tw. 
12. food*.tw. 
13. nutri*.tw. 
14. 8 or 9 or 10 or 11 or 12 or 13 
15. Agar/ 
16. agar*.tw. 
17. Alginates/ 
18. alginate*.tw. 
19. (alginic adj2 acid*).tw. 
20. Carrageenan/ 
21. carrageen*.tw 
22. exp Cellulose/ 
23. cellulose*.tw. 
24. exp Chitin/ 
25. chitin*.tw. 
26. hemicellulose*.tw. 
27. hexosan*.tw. 
28. Lignin/ 
29. lignin*.tw. 
30. Pectins/ 
31. pectin*.tw. 
32. pentosan*.tw. 
33. polydextrose*.tw. 
34. polyuronide*.tw. 
35. Raffinose/ 
36. raffinose*.tw. 
37. xanthan*.tw. 
38. Xylose/ 
39. xylose*.tw. 
40. exp Galactans/ 
41. galactan*.tw. 
42. (galactooligosaccharide* or galacto-
oligosaccharide* or gos or tos).tw. 
43. exp Fructans/ 
44. fructan*.tw. 
45. (fructooligosaccharide* or fructo-
oligosaccharide* or fos or oligofructose or oligo-
fructose).tw. 
46. exp Inulin/ 
47. Inulin*.tw. 
48. (gentiooligosaccharide* or gentio-
oligosaccharide*).tw. 
49. (isomalto oligosaccharide* or isomalto-
oligosaccharide* or imo).tw. 
50. (mannanooligosaccharide* or mannano-
oligosaccharide*).tw. 
51. (N-acetylchitooligosaccharide* or N-acetylchito-
oligosaccharide*).tw. 
52. (pectic oligosaccharide* or pectic-
oligosaccharide*).tw. 
53. (resistant starch* or resistant-starch*).tw. 
54. (soybean oligosaccharide* or soybean-
oligosaccharide*).tw. 
55. (xylooligosaccharide* or xylo-
oligosaccharide*).tw.  
56. exp Oligosaccharides/ 
57. Oligosaccharide*.tw. 
58. (fiber* or fiber* or high-fiber* or high-fiber*).tw. 
59. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 
or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 
or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 
or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 
or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58
  
60. 14 and 59 
61. 7 or 60 
62. exp Gastrointestinal Microbiome/ 
63. (microbiota or microbiome).tw. 
64. bifido*.tw. 
65. lactobacill*.tw. 
66. 62 or 63 or 64 or 65 
67. (faecal or fecal).tw. 
68. (bacteri* or flora).tw. 
69. 67 and 68 
70. exp Dysbiosis/ 
71. 66 or 69 or 70 
72. 61 and 71 
73. ((randomized controlled trial or controlled 
clinical trial).pt. or randomized.ab. or randomised.ab. 
or placebo.ab. or drug therapy.fs. or randomly.ab. or 
trial.ab. or groups.ab.) not (exp animals/ not 
humans.sh.)  
74. 72 and 73 
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Supplemental Table 3: Search algorithm: CENTRAL 
#1 MeSH descriptor: [Dietary Fiber] 
explode all trees 
#2 roughage*  
#3 MeSH descriptor: [Prebiotics] explode 
all trees 
#4 prebiotic*  
#5 carbohydrate near/2 polymer*  
#6 ((non-starch or nonstarch) near (poly-
saccharide* or polysaccharide*))  
#7 #1 or #2 or #3 or #4 or #5 or #6  
#8 MeSH descriptor: [Diet] this term only 
#9 diet*  
#10 consum*  
#11 eat*  
#12 food*  
#13 nutri*  
#14 #8 or #9 or #10 or #11 or #12 or #13  
#15 MeSH descriptor: [Agar] this term 
only 
#16 agar*  
#17 MeSH descriptor: [Alginates] this term 
only 
#18 alginate*  
#19 alginic near/2 acid  
#20 MeSH descriptor: [Carrageenan] this 
term only 
#21 carrageen*  
#22 MeSH descriptor: [Cellulose] explode 
all trees 
#23 cellulose*  
#24 MeSH descriptor: [Chitin] explode all 
trees 
#25 chitin*  
#26 hemicellulose*  
#27 hexosan*  
#28 MeSH descriptor: [Lignin] this term 
only 
#29 lignin*  
#30 MeSH descriptor: [Pectins] this term 
only 
#31 pectin*  
#32 pentosan*  
#33 polydextrose*  
#34 polyuronide*  
#35 MeSH descriptor: [Raffinose] this term 
only 
#36 raffinose*  
#37 xanthan*  
#38 MeSH descriptor: [Xylose] this term 
only 
#39 xylose*  
#40 MeSH descriptor: [Galactans] explode all trees 
#41 galactan*  
#42 (galactooligosaccharide* or galacto-
oligosaccharide* or gos or tos)  
#43 MeSH descriptor: [Fructans] explode all trees 
#44 fructan*  
#45 (fructooligosaccharide* or fructo-
oligosaccharide* or fos or oligofructose* or oligo-
fructose*)  
#46 MeSH descriptor: [Inulin] explode all trees 
#47 inulin*  
#48 (gentiooligosaccharide* or gentio-
oligosaccharide*)  
#49 (isomalto oligosaccharide* or isomalto-
oligosaccharide* or imo)  
#50 (mannanooligosaccharide* or mannano-
oligosaccharide*)  
#51 (N-acetylchitooligosaccharide* or N-acetylchito-
oligosaccharide*)  
#52 (pectic oligosaccharide* or pectic-
oligosaccharide*)  
#53 (resistant starch* or resistant-starch*)  
#54 (soybean oligosaccharide* or soybean-
oligosaccharide*)  
#55 (xylooligosaccharide* or xylo-oligosaccharide*)  
#56 MeSH descriptor: [Oligosaccharides] explode all 
trees 
#57 oligosaccharide*  
#58 fiber* or fiber* or high-fiber* or high-fiber*  
#59 #15 or #16 or #17 or #18 or #19 or #20 or #21 or 
#22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or 
#30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or 
#38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or 
#46 or #47 or #48 or #49 or #50 or #51 or #51 or #52 or 
#53 or #54 or #55 or #56 or #56 or #57 or #58  
#60 #14 and #59  
#61 #7 or #60  
#62 MeSH descriptor: [Gastrointestinal Microbiome] 
explode all trees 
#63 (microbiota or microbiome)  
#64 bifido*  
#65 lactobacill*  
#66 #62 or #63 or #64 or #65  
#67 (faecal or fecal)  
#68 (bacteri* or flora)  
#69 #67 and #68  
#70 MeSH descriptor: [Dysbiosis] explode all trees 
#71 #66 or #69 or #70  
#72 #61 and #71 
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Supplemental Table 4: Search algorithm: CINAHL 
1. ((dietary fib* OR roughage* OR prebiotic*) OR (diet* OR consum* OR eat* OR food* OR nutri*) AND 
(agar* OR alginate* OR carrageen* OR cellulose* OR chitin* OR hemicellulose* OR hexosan* OR lignin* 
OR pectin* OR pentosan* OR polydextrose* OR polyuronide* OR raffinose* OR xanthan* OR xylose* OR 
galactan* OR galactooligosaccharde* OR galacto-oligosaccharide* OR gos OR tos OR fructan* OR 
fructooligosaccharide* OR fructo-oligosaccharide* OR fos OR oligofructose* OR oligo-fructose* OR 
inulin* OR gentiooligosaccharide* OR gentio-oligosaccharide* OR isomalto oligosaccharide* OR 
isomalto-oligosaccharide* OR imo OR mannanooligosaccharide* OR mannano-oligosaccharide* OR N-
acetylchitooligosaccharide* OR N-acetylchito-oligosaccharide* OR pectic oligosaccharide* OR pectic-
oigosaccharide* OR resistant starch* OR resistant-starch* OR soybean oligosaccharide* OR soybean-
oligosaccharide* OR oligosaccharide* OR high-fib*)) 
2. ((MH “Microbiota”) OR microbiota OR microbiome OR bifido* OR lactobacill*) OR ((faecal OR fecal) AND 
(bacteri* OR flora)) OR (dysbio*) 
3. (MH "Clinical Trials+") OR (MH "Quantitative Studies") OR TI placebo* OR AB placebo* OR (MH 
"Placebos") OR (MH "Random Assignment") OR TI random* OR AB random* OR TI ((singl* or doubl* or 
tripl* or trebl*) W1 (blind* or mask*)) OR AB ((singl* or doubl* or tripl* or trebl*) W1 (blind* or mask*)) 
OR TI clinic* trial* OR AB clinic* trial* OR PT clinical trial 
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Supplemental Table 5: Reasons for excluding studies following full text analysis* 
Study Citation Reason for exclusion 
Nil author 2013 (1) Not RCT 
Alfa 2017 (2) Duplicate 
Azcarate-Peril 2013 (3) Not healthy study population 
Azcarate-Peril 2016 (4) Not healthy study population 
Azcarate-Peril 2017 (5) Not healthy study population 
Azpiroz 2016 (6) Not healthy study population 
Baer 2009 (7) Abstracts or unpublished studies 
Benus 2010 (8) Non-fiber or multifactorial intervention 
Brahe 2014 (9) Duplicate 
Brejnholt 2005 (10) Non-fiber or multifactorial intervention 
Brighenti 1999  (11) Not RCT 
Casellas 2007 (12) Not healthy study population 
Chen 2006 (13) Not RCT 
Chen 2008 (14) Not healthy study population 
Christensen 2013 (15) Non-fiber or multifactorial intervention 
Chung 2007 (16) Not RCT 
Clarke 2016 (17) Duplicate 
Clarke 2016 (18) Duplicate 
Clarke 2016 (19) Duplicate 
Cooper 2016 (20) Abstracts or unpublished studies 
Costabile 2016 (21) Not RCT 
Culpepper 2012 (22) Abstracts or unpublished studies 
Davis 2010 (23) Not RCT 
Davis 2011 (24) Not RCT 
De Preter 2007 (25) Not RCT 
Demircioglu 2008 (26) Non-fiber or multifactorial intervention 
Dewulf 2011 (27) Abstracts or unpublished studies 
Dewulf 2012 (28) Abstracts or unpublished studies 
Eastwood 1995 (29) Non-fiber or multifactorial intervention 
Eid 2015 (30) Non-fiber or multifactorial intervention 
Elison 2016 (31) Duplicate 
Famdodu 2016 (32) Abstracts or unpublished studies 
Famodu 2016 (33) Abstracts or unpublished studies 
Fava 2013 (34) Non-fiber or multifactorial intervention 
Finley 2007 (35) Did not report on review outcomes 
Ford 2017 (36) Abstracts or unpublished studies 
Gopal 2003 (37) Duplicate 
Gordon 2017 (38) Abstracts or unpublished studies 
Grasten 2000 (39) Did not report on review outcomes 
Guetterman 2016 (40) Non-fiber or multifactorial intervention 
Guglielmetti 2013 (41) Non-fiber or multifactorial intervention 
Hald 2016 (42) Not healthy study population 
Halmos 2013 (43) Duplicate 
Halmos 2014 (44) Not healthy study population 
Halmos 2015 (45) Duplicate 
Healey 2016 (46) Abstracts or unpublished studies 
Heiman 2014 (47) Not healthy study population 
Holscher 2014 (48) Duplicate 
Holscher 2015 (49) Abstracts or unpublished studies 
Hooda 2012 (50) Secondary publication 
Jalanka 2016 (51) Abstracts or unpublished studies 
Jenkins 1999 (52) Did not report on review outcomes 
Karl 2017 (53) Duplicate 
Kellow 2014 (54) Not healthy study population 
Klinder 2016 (55) Non-fiber or multifactorial intervention 
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Study Citation Reason for exclusion 
Klosterbuer 2013 (56) Did not report on review outcomes 
Kolida 2007 (57) Not RCT 
Kovatcheva-Datchary 2015 (58) Did not report on review outcomes 
Kruse 1999 (59) Not RCT 
Lambert 2014 (60) Abstracts or unpublished studies 
Lambert 2015 (61) Not healthy study population 
Lamichhane 2014 (62) Did not report on review outcomes 
Langlands 2004 (63) Not RCT 
Lappi 2013 (64) Not healthy study population 
Lee 2016 (65) Did not report on review outcomes 
Lehtinen 2012 (66) Abstracts or unpublished studies 
Li 2009 (67) Non-fiber or multifactorial intervention 
Li 2014 (68) Abstracts or unpublished studies 
Li 2015 (69) Abstracts or unpublished studies 
Lin 2014 (70) Not healthy study population 
Lin 2016 (71) Duplicate 
Linetzky 2012 (72) Not healthy study population 
Lomax 2012 (73) Duplicate 
Lomax 2013 (74) Duplicate 
Lomax 2013 (75) Abstracts or unpublished studies 
Mai 2009 (76) Abstracts or unpublished studies 
Mai 2012 (77) Non-fiber or multifactorial intervention 
Maki 2011 (78) Abstracts or unpublished studies 
Marteau 2011 (79) Not healthy study population 
Matthan 2015 (80) Abstracts or unpublished studies 
Mayengbam 2017 (81) Abstracts or unpublished studies 
Medina-Vera 2017 (82) Abstracts or unpublished studies 
Mego 2017 (83) Non-fiber or multifactorial intervention 
Mitchell 2015 (84) Not healthy study population 
Mitsou 2009 (85) Non-fiber or multifactorial intervention 
Mitsou 2011 (86) Non-fiber or multifactorial intervention 
Orrhage 2000 (87) Non-fiber or multifactorial intervention 
Pantophlet 2017 (88) Not RCT 
Ramirez-Farias 2009 (89) Secondary publication 
Ramprasath 2015 (90) Abstracts or unpublished studies 
Rao 2001 (91) Not RCT 
Ravn-Haren 2013 (92) Non-fiber or multifactorial intervention 
Robinson 2001 (93) Not RCT 
Salazar 2013 (94) Abstracts or unpublished studies 
Salazar 2015 (95) Abstracts or unpublished studies 
Salden 2015 (96) Abstracts or unpublished studies 
Salonen 2014 (97) Not healthy study population 
Scarpellini 2012 (98) Abstracts or unpublished studies 
Scarpellini 2016 (99) Did not report on review outcomes 
Scholtens 2006 (100) Did not report on review outcomes 
Sloan 2016 (101) Abstracts or unpublished studies 
Smilowitz 2017 (102) Not RCT 
Song 2015 (103) Non-fiber or multifactorial intervention 
Souza 2015 (104) Not healthy study population 
Surakka 2009 (105) Not healthy study population 
Tannock 2004 (106) Not RCT 
Taylor 2016 (107) Non-fiber or multifactorial intervention 
Thompson 2016 (108) Abstracts or unpublished studies 
Thompson 2016 (109) Abstracts or unpublished studies 
Tomono 2010 (110) Not healthy study population 
Tuohy 2001 (111) Not RCT 
Tuohy 2001 (112) Duplicate 
 Page 69 of 87 
 
Study Citation Reason for exclusion 
Ukhanova 2014 (113) Non-fiber or multifactorial intervention 
Upadhyaya 2016 (114) Not healthy study population 
Vanegas 2016 (115) Abstracts or unpublished studies 
Vanegas 2017 (116) Secondary publication 
Vanegas 2017 (117) Duplicate 
Vendrame 2011 (118) Non-fiber or multifactorial intervention 
Venkataraman 2016 (119) Not RCT 
Vitaglione 2015 (120) Non-fiber or multifactorial intervention 
Vulevic 2013 (121) Not healthy study population 
Walker 2011 (122) Not healthy study population 
Wallace 2015 (123) Not RCT 
Weickert 2011 (124) Not healthy study population 
West 2012 (125) Not RCT 
Westreich 2017 (126) Abstracts or unpublished studies 
Whisner 2016 (127) Not healthy study population 
Willis 2013 (128) Did not report on review outcomes 
Windey 2015 (129) Did not report on review outcomes 
Wong 2010 (130) Not RCT 
Wood 2017 (131) Abstracts or unpublished studies 
Wood 2017 (132) Abstracts or unpublished studies 
Worthley 2009 (133) Not RCT 
Worthley 2009 (134) Abstracts or unpublished studies 
Wutzke 2012 (135) Abstracts or unpublished studies 
Xiao 2014 (136) Not RCT 
Yang 2015 (137) Not healthy study population 
Yen 2011 (138) Duplicate 
Yen 2011 (139) Not healthy study population 
Yen 2011 (140) Not healthy study population 
 
* Citation numbers do not correspond to citations in main manuscript, and are provided at the 
end of this document. 
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Risk of Bias 
 
Supplemental Figure 1: Risk of bias across the included studies showing the summary 
percentage in each domain  
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Reporting Bias 
Supplemental Figure 2: Funnel plot for the effect of dietary fiber on Bifidobacterium spp. 
abundance  
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Supplemental Figure 3: Funnel plot for the effect of dietary fiber on Lactobacillus spp. 
abundance   
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Supplemental Figure 4: Funnel plot for the effect of dietary fiber on total fecal SCFA 
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Supplemental Figure 5: Funnel plot for the effect of dietary fiber on fecal acetate 
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Supplemental Figure 6: Funnel plot for the effect of dietary fiber on fecal propionate 
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Supplemental Figure 7: Funnel plot for the effect of dietary fiber on fecal butyrate 
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Supplemental Table 6: Outcomes of pre-defined subgroup analyses undertaken 
     Result Heterogeneity 
Outcome Subgroup 
analysis 
Subgroup 
difference (I2) 
Subgroups Studies in 
subgroup 
(n) 
Meta-analysis overall estimate 
(95% CI) 
P Chi-
squared 
test 
P I2 
Shannon 
Diversity Index 
  
Trial design 0% Cross-over 3 MD: -0.10 (95% CI: -0.19, -0.01) 0.03 1.36 0.51 0% 
   Parallel 3 MD: -0.03 (95% CI: -0.57, 0.51) 0.91 9.35 0.009 79% 
Bifidobacterium 
spp. 
Intervention 
type 
68.6% Food 10 SMD: 0.75 (95% CI: 0.52, 0.98) <0.00001  234.35  <0.00001  83% 
    Supplement 41 SMD: 0.20 (95% CI: -0.36, 0.76) 0.49 76.94 <0.00001 88% 
 Fiber type 45.3% Accepted prebiotic 23 SMD: 0.68 (95% CI: 0.38, 0.98) <0.00001  117.8 <0.00001 81% 
     Candidate prebiotic 13 SMD: 0.77 (95% CI: 0.30, 1.24) 0.001 86.19 <0.00001 86% 
     General fiber 14 SMD: 0.25 (95% CI: -0.16, 0.65) 0.24 80.54 <0.00001 84% 
 Dose 
response 
8.8% ≤5g/d 11 SMD: 0.51 (95% CI: 0.18, 0.84) 0.003 33.52 0.0002 70% 
      5-10g/d 18 SMD: 0.48 (95% CI: 0.13, 0.84) 0.007 133.22 <0.00001 87% 
     >10g/d 22 SMD: 0.85 (95% CI: 0.45, 1.25) <0.00001 143.72 <0.00001 85% 
 Trial design 77% Cross-over 30 SMD: 0.44 (95% CI: 0.21, 0.66) <0.00001 149.67 <0.00001 81% 
     Parallel 21 SMD: 0.98 (95% CI: 0.52, 1.44) <0.00001 148.63 <0.00001 87%  
 Analysis 
method 
0% Culture 13 SMD: 0.70 (95% CI: 0.07, 1.33) 0.03 99.72 <0.00001 88% 
     qPCR 11 SMD: 0.62 (95% CI: 0.29, 0.94) 0.0002 30.28 0.0008 67% 
     FISH 19 SMD: 0.71 (95% CI: 0.31, 1.10) 0.0004 187.79  <0.00001 90% 
     Sequencing 4 SMD: 0.61 (95% CI: 0.27, 0.95) 0.0005 0.83 0.84 0% 
Lactobacillus 
spp. 
Intervention 
type 
0% Food 4 SMD: 0.35 (95% CI: -0.46, 1.16) 0.40 18.73 0.00003 84% 
    Supplement 19 SMD: 0.16 (95% CI: 0.01, 0.31) 0.04 19.27 0.38 7% 
 Fiber type 69.1% Accepted prebiotic 9 SMD: 0.34 (95% CI: 0.13, 0.55) 0.002  7.63 0.47 0% 
     Candidate prebiotic 7 SMD: -0.06 (95% CI: -0.29, 0.16) 0.58 3.52 0.74 0% 
     General fiber 7 SMD: 0.22 (95% CI: -0.31, 0.75) 0.42 23.23 0.0007 74% 
 Dose 0% ≤5g/d 6 SMD: 0.16 (95% CI: -0.24, 0.56) 0.44 9.67 0.09 48% 
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     Result Heterogeneity 
Outcome Subgroup 
analysis 
Subgroup 
difference (I2) 
Subgroups Studies in 
subgroup 
(n) 
Meta-analysis overall estimate 
(95% CI) 
P Chi-
squared 
test 
P I2 
response 
      5-10g/d 5 SMD: 0.14 (95% CI: -0.12, 0.39) 0.29  3.23 0.52 0% 
     >10g/d 12 SMD: 0.29 (95% CI: -0.01, 0.59) 0.06 26.08 0.006 58% 
 Trial design 57.7% Cross-over 11 SMD: 0.08 (95% CI: -0.09, 0.25) 0.38  9.04 0.53 0% 
     Parallel 12 SMD: 0.37 (95% CI: 0.04, 0.70) 0.03 26.8 0.005 59% 
 Analysis 
method 
55.1% Culture 7 SMD: 0.61 (95% CI: 0.13, 1.08) 0.01 15.99 0.01 62% 
     qPCR 9 SMD: 0.13 (95% CI: -0.07, 0.33) 0.21 7.36 0.50 0% 
     FISH 2 SMD: -0.15 (95% CI: -0.48, 0.18) 0.37 0.01 0.94 0% 
     Sequencing 3 SMD: 0.18 (95% CI: -0.19, 0.56) 0.33 1.53 0.46 0% 
Faecalibacterium 
prausnitzii 
Dose 
response 
38.0% ≤5g/d 3 SMD: -0.10 (95% CI: -0.39, 0.19) 0.51 2.71 0.26 26% 
      5-10g/d 6 SMD: -0.05 (95% CI: -0.23, 0.13) 0.57 2.55 0.77 0% 
     >10g/d 4 SMD: 0.39 (95% CI: -0.09, 0.87) 0.11 6.24 0.10 52% 
 Trial design 53.6% Cross-over 8 SMD: 0.06 (95% CI: -0.18, 0.29) 0.63 12.71 0.08 45% 
     Parallel 5 SMD: 0.60 (95% CI: -0.09, 1.29) 0.009 22.6 0.0002 82% 
Roseburia spp. Trial design 89.2% Cross-over 2 SMD: -0.09 (95% CI: -0.46, 0.29) 0.65 0.25 0.62 0% 
    Parallel 2 SMD: 0.71 (95% CI: 0.36, 1.06) <0.00001 0.64 0.42 0% 
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Supplemental Table 7: Outcomes of post hoc subgroup analyses undertaken  
     Result Heterogeneity 
Outcome Subgroup analysis Subgroup 
difference 
(I2) 
Subgroups Studies in 
subgroup 
(n) 
Meta-analysis overall estimate 
(95% CI) 
P Chi-
squared 
test 
P I2 
Total SCFA Reporting method 44.5% Dry weight of feces 6 SMD: 0.02 (95% CI: -0.23, 0.26) 0.89 2.81 0.73 0% 
    Wet weight of feces 6 SMD: 0.25 (95% CI: 0.01, 0.49) 0.04 0.80 0.98 0% 
Acetate Reporting method 77.3% Dry weight of feces 6 SMD: -0.08 (95% CI: -0.40, 0.25) 0.65 10.26 0.07 51% 
    Wet weight of feces 10 SMD: 0.69 (95% CI: 0.05, 1.33) 0.03 98.97 <0.00001 91% 
Propionate Reporting method 0% Dry weight of feces 6 SMD: -0.07 (95% CI: -0.33, 0.20) 0.61 7.15 0.21 30% 
    Wet weight of feces 11 SMD: 0.09 (95% CI: -0.26, 0.44) 0.61 38.22 <0.00001 74% 
Butyrate Reporting method 74.1% Dry weight of feces 7 SMD: 0.02 (95% CI: -0.18, 0.22) 0.81 1.26 0.97 0% 
    Wet weight of feces 11 SMD: 0.47 (95% CI: 0.07, 0.87) 0.02 49.36 <0.00001 80% 
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